Investing.com — Belite Bio, Inc (BLTE)，一家专注于药物制剂开发的制药公司，市值达18.7亿美元，今日宣布在周二举行的年度股东大会 (AGM)上，股东通过了股东年度大会通知中概述的所有提案。根据 InvestingPro 数据显示，该公司股票表现强劲，过去一年涨幅超过60%。

The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the ...

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA – Get Free Report) saw a large increase in short interest in March.As of March 15th, there was short interest totalling 187,900 shares, an increase of 323 ...

Zentek Stock Performance Shares of Zentek stock opened at $1.17 on Friday. The stock has a 50 day moving average of $1.06 and a 200 day moving average of $0.96. The company has a debt-to-equity ...

Benchmark分析师已将其部分总和目标价调整为每股80美元，这并未考虑潜在的许可协议、加速批准的可能性或可能超出预期的定价。该公司重申的买入评级反映了对股票未来表现的信心。投资者应注意，根据 InvestingPro 的公允价值分析，该股票在当前水平上似乎被高估，下一次财报预计在2025年5月7日发布。

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dyne Therapeutics (DYN – Research Report), Quest Diagnostics (DGX – Research Report) and Belite Bio, ...

According to TipRanks.com, Jackson has 0 stars on 0-5 stars ranking scale with an average return of -18.9% and a 30.0% success rate. Jackson covers the Healthcare sector, focusing on stocks such as ...